{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:39:00Z","timestamp":1789439940568,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jocn.2022.06.025","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:09:07Z","timestamp":1657238947000},"page":"49-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Incidence of malignancies in patients with multiple sclerosis versus a healthy matched cohort: A population-based cohort study in the Netherlands using the PHARMO Database Network"],"prefix":"10.1016","volume":"103","author":[{"given":"Josephina G.","family":"Kuiper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jetty A.","family":"Overbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Foch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Boutmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meritxell","family":"Sabid\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jocn.2022.06.025_b0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/jnnp.2009.175463","article-title":"Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies","volume":"81","author":"Fois","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2022.06.025_b0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jns.2016.09.005","article-title":"Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk","volume":"370","author":"Gaindh","year":"2016","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1016\/j.jocn.2022.06.025_b0015","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/jech.58.2.142","article-title":"Skin cancer in people with multiple sclerosis: a record linkage study","volume":"58","author":"Goldacre","year":"2004","journal-title":"J Epidemiol Community Health"},{"issue":"6","key":"10.1016\/j.jocn.2022.06.025_b0020","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1600-0404.1996.tb00019.x","article-title":"Multiple sclerosis and cancer in Norway. A retrospective cohort study","volume":"93","author":"Midgard","year":"1996","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"10.1016\/j.jocn.2022.06.025_b0025","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1600-0404.1991.tb04941.x","article-title":"Cancer incidence following hospitalization for multiple sclerosis in Denmark","volume":"84","author":"Moller","year":"1991","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"10.1016\/j.jocn.2022.06.025_b0030","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/ijc.21437","article-title":"Cancer risk among patients with multiple sclerosis: a population-based register study","volume":"118","author":"Nielsen","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jocn.2022.06.025_b0035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.msard.2018.12.014","article-title":"Multiple sclerosis and cancer incidence: A Danish nationwide cohort study","volume":"28","author":"Norgaard","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.jocn.2022.06.025_b0040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12883-017-0932-0","article-title":"Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study","volume":"17","author":"Ragonese","year":"2017","journal-title":"BMC Neurol"},{"issue":"5","key":"10.1016\/j.jocn.2022.06.025_b0045","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000079947","article-title":"Cancer incidence in multiple sclerosis: a 35-year follow-up","volume":"23","author":"Sumelahti","year":"2004","journal-title":"Neuroepidemiology"},{"issue":"2","key":"10.1016\/j.jocn.2022.06.025_b0050","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/ene.12267","article-title":"Increased breast cancer risk for patients with multiple sclerosis: a nationwide population-based cohort study","volume":"21","author":"Sun","year":"2014","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.jocn.2022.06.025_b0055","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1212\/WNL.40.5.780","article-title":"A reappraisal of the epidemiology of multiple sclerosis in Olmsted County","volume":"40","author":"Wynn","year":"1990","journal-title":"Minnesota Neurology"},{"issue":"3","key":"10.1016\/j.jocn.2022.06.025_b0060","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10549-004-2229-4","article-title":"Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments","volume":"89","author":"Achiron","year":"2005","journal-title":"Breast Cancer Res Treat"},{"issue":"Pt 10","key":"10.1016\/j.jocn.2022.06.025_b0065","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1093\/brain\/aws148","article-title":"Cancer risk in multiple sclerosis: findings from British Columbia","volume":"135","author":"Kingwell","year":"2012","journal-title":"Canada Brain"},{"issue":"3","key":"10.1016\/j.jocn.2022.06.025_b0070","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1352458507083625","article-title":"Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis","volume":"14","author":"Lebrun","year":"2008","journal-title":"Mult Scler"},{"issue":"13","key":"10.1016\/j.jocn.2022.06.025_b0075","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1212\/01.wnl.0000345366.10455.62","article-title":"Cancer risk among patients with multiple sclerosis and their parents","volume":"72","author":"Bahmanyar","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jocn.2022.06.025_b0080","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1352458514564491","article-title":"A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult Scler"},{"issue":"10","key":"10.1016\/j.jocn.2022.06.025_b0085","doi-asserted-by":"crossref","first-page":"e0165027","DOI":"10.1371\/journal.pone.0165027","article-title":"Risk of Premenopausal and Postmenopausal Breast Cancer among Multiple Sclerosis Patients","volume":"11","author":"Hajiebrahimi","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jocn.2022.06.025_b0090","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2147\/CLEP.S247575","article-title":"Existing Data Sources for Clinical Epidemiology: The PHARMO Database Network","volume":"12","author":"Kuiper","year":"2020","journal-title":"Clin Epidemiol"},{"issue":"9","key":"10.1016\/j.jocn.2022.06.025_b0095","doi-asserted-by":"crossref","first-page":"A741","DOI":"10.1016\/j.jval.2017.08.2049","article-title":"Insight Into the Role of the General Practitioner in the Management of Colorectal Cancer: Record Linkage of the Netherlands Cancer Registry and the General Practitioner Database of the Pharmo Database Network","volume":"20","author":"Kuiper","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.jocn.2022.06.025_b0100","doi-asserted-by":"crossref","unstructured":"Herings RMC, Pedersen L. Pharmacy-Based Medical Record Linkage Systems. In: Brian L. Strom MD M, Stephen E. Kimmel MD M, Sean Hennessy PHARMD P, editors. Pharmacoepidemiology: John Wiley & Sons; 2012. pp. 270-86.","DOI":"10.1002\/9781119959946.ch18"},{"issue":"2","key":"10.1016\/j.jocn.2022.06.025_b0105","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ejca.2009.09.010","article-title":"New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System","volume":"46","author":"van Herk-Sukel","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jocn.2022.06.025_b0110","unstructured":"National Cancer Institute. NCI Dictionary of Cancer Terms [cited 2020. Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/invasive-cancer."},{"key":"10.1016\/j.jocn.2022.06.025_b0115","unstructured":"National Cancer Institute. Surveillance, Epidemiology and End Results Program. Available at: https:\/\/seer.cancer.gov\/seerstat\/tutorials\/aarates\/step1.html. Last accessed April 2021."},{"key":"10.1016\/j.jocn.2022.06.025_b0120","article-title":"Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study","author":"Grytten","year":"2019","journal-title":"Mult Scler J"},{"key":"10.1016\/j.jocn.2022.06.025_b0125","unstructured":"MS Trust. Contraception 2018 [cited 2020. Available from: https:\/\/www.mstrust.org.uk\/a-z\/contraception."},{"issue":"10","key":"10.1016\/j.jocn.2022.06.025_b0130","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.autrev.2012.02.001","article-title":"Updated assessment of the prevalence, spectrum and case definition of autoimmune disease","volume":"11","author":"Hayter","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.jocn.2022.06.025_b0135","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/j.seminoncol.2015.09.007","article-title":"The hallmarks of premalignant conditions: a molecular basis for cancer prevention","volume":"43","author":"Ryan","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jocn.2022.06.025_b0140","unstructured":"European Multiple Sclerosis Platform. Multiple sclerosis in Europe 2011 [cited 2020. Available from: http:\/\/www.emsp.org\/wp-content\/uploads\/2015\/08\/MS-in-EU-access.pdf."}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096758682200279X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096758682200279X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:30:46Z","timestamp":1760823046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096758682200279X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":28,"alternative-id":["S096758682200279X"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2022.06.025","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of malignancies in patients with multiple sclerosis versus a healthy matched cohort: A population-based cohort study in the Netherlands using the PHARMO Database Network","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2022.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}